The Journal of the American Medical Association (JAMA) just published an article comparing the costs of various psoriasis treatments and how they increased by 66% from 2000 to 2008, far outpacing inflation. The annual costs of treatment using biologics ranged from $18,384 to $27,577, while the annual costs for phototherapy ranged from $3,983 to $7,288! The annual costs far outweigh the price to own your own phototherapy equipment. Read more here.
The Versa-Lite™ system; phototherapy right where you need it.The revolutionary Versa-Lite™ phototherapy system puts a whole new spin on Narrowband UVB delivery. With three independently adjustable light panels that can be positioned exactly where you need them, the Versa-Lite™ system is without question the most versatile phototherapy system ever produced. Virtually any doctor's office can benefit from having a Versa-Lite™, whether it's to treat the hands, feet, scalp, or spot treatments. Click here to see our brochure, or here to read all about the new Versa-Lite™.
The FDA has issued a warning that TNF blockers (including Enbrel, Humira, Remicade and others) may cause lymphoma, leukemia and other cancers in children and teens.
Article compares clinical phototherapy with home phototherapy, finding that home treatment was both safe and resulted in patients who were happier with their treatments than patients who needed to go to the clinic to get their treatments. ... [Read more]
The maker of the psoriasis drug Raptiva (efalizumab) is pulling the drug from the U.S. market because of its association with a rare and usually fatal brain infection... [Read more]
Narrowband UVB got its start at the Dead Sea!Phototherapy and narrowband UVB is one of the safest, most effective methods for treating psoriasis, vitiligo and other skin conditions. Learn more about the birth of narrowband UVB and how it got its start at the Dead Sea! [Read more]
Phototherapy has continued to be one of the safest, most effective methods for treating vitiligo, psoriasis and eczema. Learn more about the advantages of phototherapy compared to topical and systemic medications... [Read more]
By Andrew Pollack
The New York Times - January 24, 2007
Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis. When the biotech industry began rolling out psoriasis drugs a few years ago, experts heralded the new medications as safer, more effective treatments for the skin disease... [Read more]